DOCSLIB.ORG

Additions to Automation List from 1St March 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Additions to Automation List from 1St March 2012 Additions to Automation List From 1st March 2012 Aciclovir Susp 200 Mg/5ml Sf Packsize 125 Beclometasone Dipropionate Disks 200 Mcg/Dose With Device Aciclovir Susp 400 Mg/5ml Sf Packsize 100 Packsize 120 Aconite Napellus Tabs 30 C Packsize 125 Beclometasone Dipropionate Disks 400 Mcg/Dose With Adalimumab Inj 40 Mg/0.8ml Solution For Injection In Prefilled Diskhaler Packsize 120 Pen Packsize 2 Beclometasone Dipropionate Spray 50 Mcg/Dose 200 Dose Adalimumab Inj 40 Mg/0.8ml Solution For Injection In Prefilled Packsize 1 Syringe Packsize 2 Benzalkonium Chloride Loz 500 Micrograms Sf Packsize 20 Adapalene Cream .1 % Packsize 45 Benzalkonium Chloride Loz 500 Micrograms Sf Packsize 20 Adapalene Gel .1 % Packsize 45 Benzocaine Pdr Packsize 100 Alfacalcidol Inj 2 Mcg/Ml Amp Packsize 10 Benzocaine Pdr Packsize 175 Alfacalcidol Inj 2 Mcg/Ml Amp Packsize 10 Benzoin Tinct Packsize 50 Alfentanil Inj 500 Mcg/Ml Amp Packsize 5 Benzoyl Peroxide Gel 5 % Packsize 50 Alprostadil 1000 Micrograms Sls Urethral Stick Packsize 1 Benzylpenicillin Inj 1200 Mg Vial Packsize 25 Alprostadil 250 Micrograms Sls Urethral Stick Packsize 1 Betaine Anhydrous Pdr Packsize 1 Alprostadil 500 Micrograms Sls Urethral Stick Packsize 1 Biphasic Isophane Insulin Inj 100 Units/Ml Cartridge Packsize 5 Alprostadil Inj 10 Micrograms Sls Continuation Pack Packsize 2 Blackcurrant Syrup Packsize 500 Alprostadil Inj 10 Micrograms Sls Continuation Pack Packsize 2 Bowel Cleansing Solutions Sach Packsize 1 Alprostadil Inj 10 Micrograms Starter Pack With Applicator Bryonia Tabs 30 C Packsize 125 Packsize 2 Budesonide Enema 20 Mcg/Ml Packsize 7 Alprostadil Inj 20 Micrograms Sls Continuation Pack Packsize 2 Budesonide Enema 20 Mcg/Ml Packsize 7 Alprostadil Inj 20 Micrograms Sls Continuation Pack Packsize 2 Bumetanide Tabs 5 Mg Packsize 28 Alprostadil Inj 40 Micrograms Starter Pack With Applicator Bupivacaine Hydrochloride Inj .25 % Amp Packsize 10 Packsize 2 Bupivacaine Hydrochloride Inj .25 % Polyamp Packsize 10 Alprostadil Inj 5 Micrograms Sls Vial Packsize 1 Bupivacaine Hydrochloride Inj .5 % Amp Packsize 10 Alprostadil Inj 5 Micrograms Sls Vial Packsize 1 Bupivacaine Hydrochloride Inj .5 % Polyamp Packsize 10 Amiloride Hydrochloride Soln 5 Mg/5ml Sf Packsize 150 Buprenorphine Inj 300 Mcg/Ml Amp Packsize 5 Amiloride Hydrochloride Soln 5 Mg/5ml Sf Packsize 150 Buserelin Spray 100 Micrograms Nasal Packsize 4 Amitriptyline Soln 25 Mg/5ml Sf Oral Packsize 150 Cabergoline Tabs 1 Mg Packsize 20 Amitriptyline Soln 50 Mg/5ml Sf Oral Packsize 150 Calamine Lot Oily Packsize 500 Ammonium Bicarbonate With Ipecacuanha Mixt Sf Packsize Calcarea Carbonica Tabs 30 C Packsize 84 200 Calcarea Phosphorica Tabs 6 C Packsize 125 Ampicillin Syrup 250 Mg/5ml Packsize 100 Calcium With Vitamin D Tabs Packsize 60 Amylmetacresol And Dichlorobenzyl Alcohol Loz Packsize 16 Calendula Officinalis Lot Packsize 50 Amylmetacresol And Dichlorobenzyl Alcohol Loz Packsize 24 Calendula Officinalis Oint Packsize 25 Amylmetacresol And Dichlorobenzyl Alcohol Loz Packsize 36 Camouflagers Foundation Stick Packsize 12 Amylmetacresol And Dichlorobenzyl Alcohol Loz Sf Packsize Camouflagers Pdr Finishing Packsize 20 36 Cantharis Tabs 30 C Packsize 125 Amylmetacresol And Dichlorobenzyl Alcohol With Ascorbic Acid Cantharis Tabs 6 C Packsize 125 Loz Packsize 36 Carbamazepine Supps 125 Mg Packsize 5 Anastrozole Tabs 1 Mg Packsize 28 Carbamazepine Supps 125 Mg Packsize 5 Apomorphine Hydrochloride Inj 10 Mg/Ml Amp Packsize 5 Carbamazepine Supps 250 Mg Packsize 5 Apomorphine Hydrochloride Inj 10 Mg/Ml Amp Packsize 5 Carbamazepine Supps 250 Mg Packsize 5 Apomorphine Hydrochloride Inj 10 Mg/Ml Amp Packsize 5 Carbo Vegetabilis Tabs 30 C Packsize 125 Apomorphine Hydrochloride Inj 10 Mg/Ml Pen Packsize 5 Carbo Vegetabilis Tabs 6 C Packsize 125 Apomorphine Hydrochloride Inj 5 Mg/Ml Solution For Infusion Carnitine Liq 1 G/10ml Vial Oral Packsize 1 Packsize 5 Causticum Tabs 200 C Packsize 125 Aripiprazole Inj 7.5 Mg/Ml Vial Packsize 1 Causticum Tabs 30 C Packsize 125 Aripiprazole Soln 1 Mg/Ml Oral Packsize 150 Causticum Tabs 30 C Packsize 125 Aripiprazole Tabs 30 Mg Packsize 28 Cefadroxil Caps 500 Mg Packsize 20 Arnica Oil Massage Balm Packsize 10 Cefalexin Caps 500 Mg Packsize 28 Arnica Oil Massage Balm Packsize 50 Cefalexin Susp 250 Mg/5ml Packsize 100 Arsenicum Album Tabs 6 C Packsize 125 Ceftazidime Inj 2 G Vial Packsize 1 Ascorbic Acid Pdr Packsize 100 Ceftazidime Inj 500 Mg Vial Packsize 1 Aspirin Supps 150 Mg Packsize 10 Ceftriaxone Sodium Inj 1 G Vial Packsize 5 Atazanavir Caps 300 Mg Packsize 30 Ceftriaxone Sodium Inj 2 G Vial Packsize 1 Atorvastatin Tabs 10 Mg Chewable Packsize 30 Ceftriaxone Sodium Inj 2 G Vial Packsize 1 Atovaquone Susp 750 Mg/5ml Sf Packsize 210 Ceftriaxone Sodium Inj 250 Mg Vial Packsize 1 Atropine Sulphate Inj 600 Mcg/Ml Amp Packsize 10 Cetirizine Tabs 10 Mg Allergy Packsize 7 Aurum Metallicum Tabs 200 C Packsize 50 Cetylpyridinium Chloride Loz 1.4 Mg Packsize 24 Avena Sativa Tinct Mother Packsize 30 Cetylpyridinium Chloride With Chlorocresol And Lidocaine Avena Sativa Tinct Mother Packsize 50 Hydrochloride Gel Sf Teething Packsize 10 Azithromycin Drops 15 Mg/G Single Dose Unit Eye Preservative Chamomilla Grans 30 C Packsize 7 Free Packsize 6 Chloral Hydrate Pdr Packsize 100 Azithromycin Drops 15 Mg/G Single Dose Unit Eye Preservative Chlorambucil Tabs 2 Mg Packsize 25 Free Packsize 6 Chlorhexidine Digluconate And Tetracaine Hydrochloride Sf Bandages Icthaband Packsize 1 Packsize 1 Bandages Zinc Paste 15% Packsize 1 Chlorhexidine Gluconate Cream 1 % Packsize 250 Bandages Zinc Paste And Ichthammol Packsize 1 Chlorhexidine Gluconate Lot .1 % Medicated Cleansing Bandages Zincaband 15% Packsize 1 Packsize 150 Beclometasone Dipropionate Disks 100 Mcg/Dose With Device Chlorhexidine Gluconate Lot .1 % Medicated Cleansing Packsize 120 Packsize 150 Beclometasone Dipropionate Disks 100 Mcg/Dose With Chlorhexidine Gluconate Sol .05 % Sachet Packsize 10 Diskhaler Packsize 120 Chlorhexidine In Isopropyl Alcohol Sach Pre Injection Swab Denosumab Inj 60 Mg Solution For Injection In Prefilled Syringe Packsize 100 Packsize 1 Chlorphenamine Maleate Elix 2 Mg/5ml Sf Packsize 150 Dequalinium Chloride Loz 250 Micrograms Packsize 20 Chlorphenamine Maleate Elix 2 Mg/5ml Sf Packsize 150 Dequalinium Chloride Loz 250 Micrograms Packsize 40 Chlorphenamine Maleate Inj 10 Mg/Ml Amp Packsize 5 Desferrioxamine Mesilate Inj 2 G Vial Packsize 1 Chlorpromazine Hydrochloride Inj 25 Mg/Ml Amp Packsize 10 Desferrioxamine Mesilate Inj 2 G Vial Packsize 1 Chlorpromazine Hydrochloride Inj 25 Mg/Ml Amp Packsize 10 Desferrioxamine Mesilate Inj 500 Mg Vial Packsize 10 Chlorpromazine Hydrochloride Tabs 25 Mg Packsize 28 Desferrioxamine Mesilate Inj 500 Mg Vial Packsize 10 Choriogonadotropin Alfa Inj 250 Micrograms Prefilled Syringe Desloratadine Tabs 5 Mg Packsize 30 Packsize 1 Desloratadine Tabs 5 Mg Packsize 30 Chorionic Gonadotrophin Inj 1500 Units Amp With Solvent Desmopressin Inj 4 Mcg/Ml Amp Packsize 10 Packsize 1 Desmopressin Inj 4 Mcg/Ml Amp Packsize 10 Chorionic Gonadotrophin Inj 5000 Units Amp With Solvent Dexamethasone Elix 500 Mcg/5ml Packsize 125 Packsize 1 Dexamethasone Inj 3.3 Mg/Ml Solution For Injection Amp Cilostazol Tabs 50 Mg Packsize 56 Packsize 5 Citric Acid Pdr Packsize 50 Dexamethasone Inj 3.3 Mg/Ml Solution For Injection Amp Clobetasol With Neomycin And Nystatin Cream Packsize 5 0.05%/0.5%/100000 Units Per G Packsize 30 Dexamethasone Inj 4 Mg/Ml Vial Packsize 5 Clobetasol With Neomycin And Nystatin Oint Dexamethasone Tabs 2 Mg Packsize 500 0.05%/0.5%/100000 Units Per G Packsize 30 Dexketoprofen Tabs 25 Mg Packsize 20 Clonazepam Inj 1 Mg/Ml Amp Packsize 5 Diamorphine Hydrochloride Pdr Packsize 25 Clonazepam Inj 1 Mg/Ml Amp Packsize 5 Diazepam Supps 10 Mg Packsize 6 Clozapine Tabs 100 Mg Packsize 28 Diazepam Tubes 2 Mg/Ml Rectal Packsize 5 Clozapine Tabs 100 Mg Packsize 28 Diazepam Tubes 2 Mg/Ml Rectal Packsize 5 Clozapine Tabs 25 Mg Packsize 28 Diazepam Tubes 2 Mg/Ml Rectal Packsize 5 Clozapine Tabs 50 Mg Packsize 50 Diazepam Tubes 2 Mg/Ml Rectal Packsize 5 Coal Tar Sol Strong Packsize 500 Diazepam Tubes 2 Mg/Ml Rectal Packsize 5 Co-Amoxiclav Inj Vial 500mg/100mg Packsize 10 Diazepam Tubes 4 Mg/Ml Rectal Packsize 5 Co-Amoxiclav Inj Vial 500mg/100mg Packsize 10 Diazepam Tubes 4 Mg/Ml Rectal Packsize 5 Co-Codamol Tabs 15/500mg Effervescent Packsize 100 Dibromopropamidine Isetionate Cream .15 % Packsize 25 Co-Codamol Tabs 15mg/500mg Packsize 100 Diclofenac Caps 100 Mg Packsize 28 Co-Codamol Tabs 8mg/500mg Packsize 100 Diclofenac Gel 1 % P Aqueous Pump Dispenser Packsize 75 Coconut Oil Unlicensed Packsize 500 Diclofenac Supps 12.5 Mg Paediatric Packsize 10 Coffea Cruda Tabs 200 C Packsize 250 Diclofenac Supps 25 Mg Packsize 10 Co-Fluampicil Syrup 125mg/125mg In 5ml Packsize 100 Diclofenac Supps 25 Mg Packsize 10 Colestipol Hydrochloride Sach 5 G Packsize 30 Diclofenac Tabs 12.5 Mg Packsize 10 Colistin Inj 1 Mega Units Vial Packsize 10 Diclofenac Tabs 75 Mg Packsize 28 Colocynthis Grans 30 C Packsize 14 Diclofenac Tabs 75 Mg Packsize 56 Colocynthis Grans 30 C Packsize 25 Dihydrotachysterol Soln 250 Mcg/Ml Oral Packsize 15 Colocynthis Grans 30 C Packsize 7 Diltiazem Hydrochloride Caps 240 Mg Packsize 28 Colocynthis Grans 6 C Packsize 7 Diltiazem Hydrochloride Caps 300 Mg Packsize 28 Colocynthis Pdr 30 C Packsize 1 Disodium Pamidronate Inj 90 Mg Vial Packsize 1 Colocynthis Tabs 30 C Packsize 125 Dithranol, Coal Tar And Salicylic Acid Gel Scalp Packsize 50 Compound Preparations With Salicylic Acid Paint Packsize Docusate Sodium
Load more

Recommended publications
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Chewable Lozenge Formulation
    Umashankar M S et al. Int. Res. J. Pharm. 2016, 7 (4) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Review Article CHEWABLE LOZENGE FORMULATION- A REVIEW Umashankar M S *, Dinesh S R, Rini R, Lakshmi K S, Damodharan N SRM College of Pharmacy, SRM University, Kattankulathur, India *Corresponding Author Email: [email protected] Article Received on: 11/02/16 Revised on: 13/03/16 Approved for publication: 28/03/16 DOI: 10.7897/2230-8407.07432 ABSTRACT Development of lozenges dated back to 20thcentury and is still remain popular among the consumer and hence it has continued commercial production. Lozenges are palatable solid unit dosage form administrated in the oral cavity. They meant to be dissolved in mouth or pharynx for its local or systemic effect. Lozenge tablets provide several advantages as pharmaceutical formulations however with some disadvantages. Lozenge as a dosage form can be adopted for drug delivery across buccal route, labial route, gingival route and sublingual route. Multiple drugs can also be incorporated in them for chronic illness treatments. Lozenge enables loading of wide range of active ingredients for oral systemic delivery of drugs. Lozenges are available as over the counter medications in the form of caramel based soft lozenges, hard candy lozenges and compressed tablet lozenges containing drugs for sore throat, mouth infection and as mouth fresheners. The rationale behind the use of medicated lozenges as one of the most favored dosage form for the delivery of antitussive drugs. This review focuses various aspects of lozenge formulation providing an insight to the formulation scientist on novel application of lozenge drug delivery system.
    [Show full text]
  • Substantial Equivalence Determination Decision Summary Assay Only Template
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k091024 B. Purpose for Submission: Premarket notification C. Measurand: Methicillin Resistant Staphylococcus aureus (MRSA) D. Type of Test: Detection of MRSA using a selective and differential chromogenic media E. Applicant: bioMérieux, Inc. F. Proprietary and Established Names: chromID™ MRSA Agar G. Regulatory Information: 1. Regulation section: 21 CFR 866.1700 2. Classification: Class II 3. Product code: JSO Culture media, Antimicrobial susceptibility test, excluding Mueller Hinton Agar 1 4. Panel: Microbiology H. Intended Use: 1. Intended use(s): chromID™ MRSA agar is a selective and differential chromogenic medium for the qualitative detection of nasal colonization of methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on anterior nares swab specimens from patients and healthcare workers to screen for MRSA colonization. chromID™ MRSA agar is not intended to diagnose MRSA infection nor to guide or monitor treatment of infection. 2. Indication(s) for use: The chromID™ MRSA agar is not intended to diagnose MRSA infection nor to guide or monitor treatment of infection. 3. Special conditions for use statement(s): Prescription use 4. Special instrument requirements: Not applicable I. Device Description: The chromID™ MRSA agar is translucent and a light tan color. After the plates are inoculated and incubated, colonies growing on the plates will have either a green appearance, which indicates a positive MRSA status or a colorless appearance which indicates a negative MRSA status. The green color is more vivid if the colonies are observed through the agar from the bottom of the plate.
    [Show full text]
  • Adverse Effects and Precautions
    1736 Disinfectants and Preservatives i Amylmetacresoi (BAN, riNN) ..................Preparat ons........ Adverse Effects and Precautions ProprietaryPreparations (details are given in Volume B) The alkyl gallates may cause contact sensitivity and skin Aml!metacreso!; A[ililrnetakrezol: Amylrnet.acreso[; Amylrne.­ AM<InM<;· Multi-ingredient Preparations. Singapore: Esemdent. reactions. ta�resolurn; Amylmetakresol: Amyylirnetakresoli; TaKpe30J1. Effects on the blood. Methaemoglobinaemia associated 6-Pentyl-rn,cresol; S;Methyl.-2-pentylpheooi. Alkyl Gallates with the antoxidants (butylated hydroxyanisole, butylated C1 J1,80= 178.3 hydroxytoluene, and propyl gallate) used to preserve the CAS 1300,94-3. .de Gaiatos alquilo; AnKwnrannalJ:>t. oil in a soybean infant feed fom1ula has been reported.1 UN!! -'-· 05W904P57F: Propyl gallate was suspected of being the most likely cause Dodecyl Gallate because its chemical structure is similar to pyrogallol Pharmacopoeias. In Bur. (see p. vii). (p. 1718.2), a methaemoglobinaemia inducer. Ph. Eur. 8: (Amylmetacresol). A clear or almost clear liquid Dodecilo galatas; Dociecyle,. gallate Dodecylgallat; . de; ..•. I. Nitzan M, et al. Infantile methemoglobinemia caused by food additives. or a solid crystalline mass, colourless or slightly yellow Dodecyi-9Jilat; D(0ec%lis (iallas:. Dodekyyligallaattl; E312; Clin Toxicol 1979; 15: 273-80. when freshly prepared; it darkens or discolours to dark m Galata • de dodecflo; Laury! Gailate; Laurylum Gafikw ; yellow, brownish-yellow, or pink on keeping. F.p. about 22 }logel\vfn rarinar. Preparations degrees. Practically insoluble in water; very soluble in Dodecyi 3,4,5-trihyc;lroxybenzoate. ...................... alcohol and in acetone. Store in non�metallic airtight (details are given in Volume B) C;ul;lje0$=338.4 ProprietaryPreparations containers. Protect from light.
    [Show full text]
  • Study Protocol
    Study Protocol Proposed methodology to measure the impact of GRIP toolkit materials on antibiotic prescribing for URTIs by primary care physicians The method described here illustrates the process for assessment of one specific symptom of upper respiratory tract infection (URTI), sore throat. This has been selected as the Centor criteria may be used to predict the likelihood of a group A streptococcal bacterial infection in patients complaining of acute sore throat1 while other common URTI symptoms are likely to be due to viral infection. This protocol can be adapted for other URTI symptoms. Using this protocol and analysing the collected data can help understand: • The impact of GRIP toolkit materials on antibiotic prescribing in URTIs • Thether current level of antibiotic use is indicated (e.g. in non-high risk patients) Study arms • Control arm: no access to GRIP toolkit materials (n=tbc) • Test arm: full access to GRIP toolkit materials (n=tbc) Test arm: GRIP URTI toolkit preparation prior to assessment If you are part of the control arm and will not be using the toolkit during this assessment, you do not need to read this section. Please go straight to the patient section below. Preparation and planning • Review current personal and colleague management practices when dealing with URTIs, specifically acute sore throat • Ensure each doctor within the test arm has read and understood the toolkit materials • Identify any differences between current practice versus that advised in the GRIP toolkit Defining use of the GRIP toolkit There are four ways the GRIP toolkit can be used by the test arm.
    [Show full text]
  • 2012 Harmonized Tariff Schedule Pharmaceuticals Appendix
    Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5
    [Show full text]
  • Sore Throat in Primary Care Project
    Family Practice, 2015, Vol. 32, No. 3, 263–268 doi:10.1093/fampra/cmv015 Advance Access publication 25 March 2015 Epidemiology Sore throat in primary care project: a clinical score to diagnose viral sore throat Selcuk Mistika,*, Selma Gokahmetoglub, Elcin Balcic, and Fahri A Onukd Downloaded from https://academic.oup.com/fampra/article-abstract/32/3/263/695324 by guest on 31 July 2019 aDepartment of Family Medicine, bDepartment of Microbiology, cDepartment of Public Health, Erciyes University Medical Faculty, Kayseri, Turkey, and dBunyamin Somyurek Family Medicine Centre, Kayseri, Turkey. *Correspondence to Prof. S. Mistik, Department of Family Medicine, Erciyes University Medical Faculty, Kayseri 38039, Turkey; E-mail: [email protected] Abstract Objective. Viral agents cause the majority of sore throats. However, there is not currently a score to diagnose viral sore throat. The aims of this study were (i) to find the rate of bacterial and viral causes, (ii) to show the seasonal variations and (iii) to form a new scoring system to diagnose viral sore throat. Methods. A throat culture for group A beta haemolytic streptococci (GABHS) and a nasopharyngeal swab to detect 16 respiratory viruses were obtained from each patient. Over a period of 52 weeks, a total of 624 throat cultures and polymerase chain reaction analyses were performed. Logistic regression analysis was performed to find the clinical score. Results. Viral infection was found in 277 patients (44.3%), and GABHS infection was found in 116 patients (18.5%). An infectious cause was found in 356 patients (57.1%). Rhinovirus was the most commonly detected infectious agent overall (highest in November, 34.5%), and the highest GABHS rate was in November (32.7%).
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • An Overview of Throat Lozenges and Sprays in the Management of Pharyngitis at Primary Care Level
    REVIEW An overview of throat lozenges and sprays in the management of pharyngitis at primary care level L Wadesango, N Nxumalo, N Schellack School of Pharmacy, Sefako Makgatho Health Sciences University Corresponding author: Lucille Malan ([email protected]) Abstract Pharyngitis, or sore throat, is most commonly a symptom of pharyngeal inflammation and is a common complaint among children, adolescents and adults. Medicinal lozenges and throat sprays form an essential part of the management of pharyngitis or sore throat at primary care level. The pharmacist should ensure that patients understand how to correctly use the throat spray applicator, and not exceed the recommended dosages of these products. This article provides a brief overview of these products and their use in the management of pharyngitis. Keywords: medicinal lozenge, pharyngitis, throat sprays © Medpharm S Afr Pharm J 2019;86(2):17-20 Introduction Symptoms of sore throat Pharyngitis, or sore throat, is most commonly a symptom of Patients reporting to a primary care facility with a sore throat pharyngeal inflammation and is a common complaint among may also present with a number of the following signs and children, adolescents and adults.1 It refers to a painful sensation symptoms1,3-4: 2 and inflammation of the pharynx (back of throat). Viral infections, • Localised pain and mucosal oedema (localised swelling) such as a common cold or influenza, or a substantial bacterial • Husky or hoarse voice infection, such as tonsillitis, are possible causes of a sore throat.3 Most sore throats will resolve without treatment because they are • Odynophagia (painful swallowing when eating or drinking) often associated with a self-limiting viral upper respiratory tract • Dysphagia (having difficulty swallowing) infection (at least 70% are due to less severe cold and flu virus • Dryness of the throat infections).4 Symptomatic relief with throat sprays and lozenges • A scratchy or irritated sensation at the back of the throat is generally advised for patients with uncomplicated pharyngitis.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Verification and Validation of Analytical Methods for Testing the Levels of Pphcps (Pharmaceutical & Personal Health Care Pr
    Verification and Validation of Analytical Methods for Testing the Levels of PPHCPs (Pharmaceutical & Personal Health Care Products) in treated drinking Water and Sewage Report to the Water Research Commission by Cecilia S. Osunmakinde, Oupa S. Tshabalala, Simiso Dube & Mathew M. Nindi Chemistry Department, University of South Africa WRC Report No. 2094/1/13 ISBN 978-1-4312-0441-0 July 2013 Obtainable from: Water Research Commission Private Bag X03 GEZINA, 0031 [email protected] or download from www.wrc.org.za DISCLAIMER This report has been reviewed by the Water Research Commission (WRC) and approved for publication. Approval does not signify that the contents necessarily reflect the views and policies of the WRC, nor does mention of trade names or commercial products constitute endorsement or recommendation for use. ©Water Research Commission ii Pharmaceutical and personal health care products in treated drinking water and sewage ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ EXECUTIVE SUMMARY ______________________________________________________________________________________ Thousands of metric tons of pharmaceutical and personal care products (PPCPs) are being produced and consumed worldwide per year. This group of emerging contaminants has recently received scrutiny from various communities because their fate and impact on the aquatic environment are not well understood. Since the challenge of water shortages is becoming a reality worldwide, alternatives for protecting the resource such as recycling are being considered. However, such alternatives create concerns relating to the quality of the water especially where the emerging contaminants are not being monitored. There have been reports of the presence of these PPHCPs in water systems although at low concentration levels of microgram to nanogram per litre. It is known though that even at such low concentrations some groups of PPHCPs such as endocrine disrupting compounds may have an adverse effect on aquatic organisms.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]